Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : analysts and calls -- B of A -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (6)	10/15/2002 7:52:51 PM
From: Miljenko Zuanic	Respond to of 33

He also started ITMN with strong buy and REGN with buy.

To: Icebrg who wrote (6)	11/15/2002 11:33:27 AM
From: Icebrg	Read Replies (2) \| Respond to of 33

Neurocrine Biosciences downgraded by Banc of America Sec - Briefing.com. From Strong Buy to Buy. Share price was @ 48 USD. Cephalon downgraded by Banc of America Sec - Briefing.com From Buy to Market Perform. Share price was @ 58.41. I have no seen any further comments. It may be noted that a month ago coverage was initiated for Cephalon (Mike King) with a Buy rating (which they now took away) and a 12-month target price of USD 59. I suppose Mike just now is considering what his next move should be. Declaring 11 months of dead money or raising the target price. Erik